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Abstract 
The advantages of oral dosage form that are responsible for its popularity are its ease of 
administration, patient compliance and stability of formulation. The most popular oral dosage 
forms beings tablets and capsules, but one important drawback of the dosage forms however 
is the difficulty to swallow especially when a dosage form is developed for pediatric and 
geriatric patient. The modern scientific and technological advancement in the pharmaceutical 
field had created bank of interest in reconstitutable oral suspension dosage form in the recent 
year. The reconstituted system is the formulation of choice when the drug stability is a major 
concern. Reconstitutable oral systems show the adequate chemical stability of the drug during 
shelf life and also reduce the weight of the final product.  Dry syrup form of the drug is also 
useful in case of bioavailability as it has high bioavailability rather than tablets and capsules 
as it disintegrates in water outside of the oral cavity and directly the suspension is gone 
through the gastrointestinal tract. So the suspension easily absorbs in the GIT. The present 
review gives an account of the excipients used, methods of preparation of dry syrups along 
with their evaluations, their packaging, ICH guidelines. 
Introduction 
Pharmaceutical dosage form can be divided into various 
classes. Classification of dosage form shown in table no. 1. 
Table no. 1: Classification of dosage form 
Dosage Form Advantages Disadvantages 
Solid dosage 
form 
Eg. Tablet, 
Capsule, 
Suppository, 
Powder 
Most stable dosage 
form 
Cost effective 
Less microbial 
Contamination 
Pediatric and geriatric 
as wellas seriously ill 
patient cannot swallow. 
Some drugs resists to 
compress into dense 
compacts 
Semi-solid 
dosage form 
Eg. Paste, 
Cream, Gel, 
Ointment 
Generally used 
externally 
Reduced side effects 
Local action 
No dosage accuracy 
The base which is used 
can be easily oxidised 
 
Liquid dosage 
form 
Eg. Solution, 
Suspension, 
Syrup 
More rapid action 
Useful for the patient 
who have difficulty in 
swallowing 
solid dosage form 
 
Less stable dosage form 
Difficult for 
transportation 
Less dosage accuracy 
Vapor dosage 
form 
Eg. Inhalation 
therapy, 
Aerosol 
Local action 
Some drugs are only 
administered by this 
type of dosage form 
For preparing this type 
of dosage form more 
excipients and 
equipment required. 
 
An oral route is the most preferred route of administration 
[1]
.Tablets and capsules are unsuitable for administering high 
doses of Active Pharmaceutical Ingredient (API) since 
individual large dose is difficult to swallow, or require the 
administration of several tablets or capsules at a time, making 
it less patient compliant. Due to need of chewing, poor taste 
masking and lack of control release possibility chewable 
tablets are not ideal with pediatric and geriatric patients. Oral 
liquid suspensions are mainly formulated for the patients with 
difficulty in swallowing. But controlled release form of liquid 
suspension is difficult due to the chances of early release of 
the API in the suspending media during storage. Hence it is 
essential to develop a reconstitutable suspension dosage form 
[2]
.  
Dry Syrups: “Dry pharmaceutical syrup may be defined as a 
finely divided insoluble particle ranging from 0.5-5 μ, which 
is to be distributed in a suitable vehicle”. 
Dry syrups are the solid dosage form that can be reconstituted 
by the addition of water to administer by the oral route. 
Mostly antibiotics, some moisture sensitive and pediatric 
drugs are available in the form of dry syrup [3]. 
Many preparations like Amoxicillin trihydrate, Erythromycin 
ethyl succinate, Dicloxacillin sodium etc. are available as dry 
powder mixtures or granules that are intended to be suspended 
in water or some other vehicle before oral administration. The 
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reconstituted system is the formulation of choice when the 
drug stability is a major concern. The dry mix for oral 
suspension contains the drug, colorants, flavors, sweeteners, 
stabilizing agents, suspending agents and preserving agents 
that may be needed to enhance the stability of the formulation. 
Dry syrup form of drug shows improved bioavailability as 
compared to tablets and capsules as it is in the dispersed state 
at the time of administration. A reconstitutable suspension can 
offer several advantages such as maintenance of the chemical 
stability of the active compounds until reconstitution at the 
start of treatment. The same suspension can be easily 
administered to children of different ages by adjusting the 
volume to swallow [3, 4]. 
Suspension: A Pharmaceutical suspension is a coarse 
dispersion in which internal phase is dispersed uniformly 
throughout the external phase. The internal phase consisting of 
insoluble solid particles having a specific range of size which 
is maintained uniformly throughout the suspending vehicle 
with  the help of single or combination of suspending agent. 
The external phase (suspending medium) is usually aqueous in 
some case, may be an organic or oily liquid for non-oral use 
[5].  
Classification of Suspension
[5, 6]
 
Suspension is classified based on various parameters. 
Suspension is classified as below: 
Based on Route of administration  
 Oral suspension  
 Topical suspension  
 Parenteral suspension  
Based on Proportion of Solid content  
 Dilute suspension (2 to10%w/v solid)  
 Concentrated suspension (10 to 50% w/v solid) 
Based on Electro kinetic Nature of Solid Particles 
 Flocculated suspension  
 Deflocculated suspension  
Based on Size of Solid Particles 
 Colloidal suspension (< 1 micron)  
 Coarse suspension (>1 micron)  
 Nano suspension (10 ng)  
Based on Method of Administration 
 Dry powder for reconstitution  
 Ready to use suspension 
Based on Release 
 Conventional suspension 
 Sustained release suspension 
Advantages of Sustained/Controlled release drug delivery 
system over the conventional dosage form
[1, 7-11]
 
Sustained release drug delivery is novel drug delivery system 
which has many advantages over conventional dosage form. 
1. Dosing frequency reduced due slow release 
2. Dose reduction 
3. Better patient compliance 
4. Reduction in gastrointestinal irritation due to 
decrease in local and systemic side effects. 
5. Constant level of drug concentration in blood 
plasma 
6. Reduces chances of toxicity due to overdose 
7. Reduced healthcare costs through improved 
therapy 
8. Reduces the fluctuation of peak valley 
concentration 
9. Night time dosing can be avoided 
Drug selection criteria for sustained release dosage forms
[1, 
3, 12]
 
For preparation of sustained release dosage form drug should 
follow below criteria. 
1. Desirable half-life: The half-life of a drug is residence 
time of drug in the body. Preferably, the drug should have 
half-life of three to four hours. If half-life of drug is more 
than no need to prepare sustained release dosage form. 
2. High therapeutic index: Drugs with low therapeutic 
index are unsuitable for incorporation in sustained release 
formulations. If the system fails in the body, dose 
dumping may occur, leading to fatalities. eg.Digitoxin. 
3. Small dose:Minimum dose is preferred for sustained 
release formulation because the size of a unit dose 
sustained release formulation would become too big, to 
administer without difficulty. 
4. Desirable absorption and solubility characteristics: 
Absorption of poorly water soluble drug is often 
dissolution rate limited. Incorporating such compounds 
into sustained release formulations is therefore 
impractical and may decrease overall absorption 
efficiency.  
5. Desirable absorption window: Certain drugs when 
administered orally are absorbed only from a specific part 
of gastrointestinal tract. This part is called as the 
„absorption window‟. Drugs exhibiting an absorption 
window like fluorouracil, thiazide diuretics, if formulated 
as sustained release dosage form are unsuitable.  
6. First pass clearance: Delivery of the drug to the body in 
desired concentrations is really hampered in case of drugs 
undergoing extensive hepatic first pass metabolism, when 
administered in sustained release forms.  
Qualities of ideal oral suspension
[2, 5, 12, 13]
 
1. The dispersed particle should not settle readily and the 
settle particles should redispersesuddenly.  
2. On settling cake should not form by the particle. 
3. Preparation can be easily poured.  
4. It should be chemically and physically stable.  
5. It should be palatable.  
6. It should be free from gritting particle. 
Disadvantages of liquid oral suspensions [12, 14]
 
Liquid oral suspension has certain disadvantages. To 
overcome these disadvantages reconstitutable suspension 
prepared. 
(1) There are chances of inaccuracy in single dosing because 
it is a bulk formulation  
(2) Drug dose depends on various physical factors of the 
dosage form such as temperature of storage, 
sedimentation rate of the formulation, liquid flow 
properties like viscosity, pourability, redispersion, 
flocculation and content uniformity.  
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(3) The drug may be less stable in a liquid formulation 
rather than in tablets or capsules. 
(4) Stability of the liquid suspension largely depends on the 
temperature of storage.  
(5) Caking occurs upon storage. 
Advantages of dry granules for oral suspension[3, 14] 
(1) There is accurate single dosing as the dose is packed in 
single dose sachets. 
(2) Drug dose is relatively independent of any physical 
factors like temperature, sedimentation rate and liquid 
flow properties.  
(3) Packaging of the powder mixture is done in sachets 
(single dose) making the formulation easy to carry.  
(4) Enhanced convenience of single dosage regimen.  
(5) Colored, flavored, sweetened formulation is 
advantageous for administration to the pediatric 
population.  
(6) Stable on storage and when reconstituted with an 
ingestible liquid for administration, the corresponding 
liquid suspension is stable for the duration for which the 
therapy is required.  
Required Characteristics of Suspensions for 
Reconstitution
[14, 15]
 
1. Powder blend must be a uniform mixture of the suitable 
concentration of each ingredient. During reconstitution, 
the powder blend must disperse rapidly and completely in 
the aqueous vehicle.   
2. Reconstituted suspension must be easily re-dispersed and 
poured by the patient to provide exact and uniform dose.  
3. After reconstitution the high viscosity caused by the 
refrigerated storage temperatures should not obstruct dose 
administration by the patient. 
4. Final product must have an acceptable appearance, odor 
and taste. 
Reasons for formulation of such suspensions
[16] 
Reconstitute suspension is formulated due many reasons such 
as for patient which have difficulty in swallowing, drug 
stability etc. Some reasons are discussed below. 
1. The main reason for the formulation of suspensions for 
reconstitution is inadequate chemical stability of the 
drug in an aqueous vehicle.  
2. Another reason for the formulating suspensions for 
reconstitution is to avoid the physical stability problems. 
These problems include possible increased drug 
solubility due to pH changes from chemical degradation, 
incompatibility of ingredients, viscosity changes, 
conversion of polymorphic form and crystal growth and 
caking.   
3. Formulation for reconstitution reduces the weight of the 
final product because the aqueous vehicle is absent and 
consequently, transportation expenses may be reduced. 
4. Suspension for reconstitution is convenient dosage form 
for large doses [2]. 
5. Safe and compliant for pediatric and geriatric patient.  
6. Suitable for insoluble or poorly soluble API. 
Excipients used 
[3, 16]
 
Number of excipients should be minimum as more the number 
of excipients in the formulation, the greater is the possibility 
of problems, for example, the chances of compatibility 
problems are increased as more excipients are used. More 
processing is required to incorporate more excipients. For 
reducing the number of excipients use an excipient that 
performs more than one function. Eg. Sucrose can be used as a 
diluents, sweetener and suspending agent.  
All excipients should disperse rapidly on reconstitution. This 
criterion eliminates several suspending agents.  
Granule disintegrant: It results in prevention of the particle 
aggregation.  
Granule binder: It helps to reduce the settling of particles in 
suspensions. It is also used as a stabilizer for suspensions. 
Eg.High molecular weight povidone.   
Suspending agents 
Suspending agents should be easily dispersed during 
reconstitution. These rules out several common suspending 
agents because many require hydration, elevated temperatures 
or high shear mixing for adequate dispersion. Some of the 
suspending agents that are recommended for use are Acacia, 
Carboxymethylcellulose sodium, Iota 
carrageenan,Microcrystalline cellulose with 
carboxymethylcellulose sodium, Silicon dioxide, Sodium 
starch glycolate, Tragacanth, Xanthan gum.  
Xanthan gum is a common suspending agent in suspensions 
for reconstitution. Its solution viscosity is practically 
independent of pH and temperature. 
Sweeteners 
Sweeteners can mask the unfavorable taste and enhance 
patient acceptance in the pediatric population that uses this 
product. The sweetener is a significant component of 
suspensions for reconstitution. Drugs frequently have a bitter 
taste and suspending agents, particularly clays, may have a 
bland taste.  
Eg. Sucrose can perform both functions of sweetener and 
suspending agent, and serve as a diluent in the dry mixture. 
Saccharin may become restricted by the Food and Drug 
Administration because of its carcinogenic potential. Others 
include Mannitol, Dextrose, Aspartame, Saccharin Sod. 
Wetting agents 
Many drugs in suspension are hydrophobic; they repel water 
and are not easily wetted. Must select the appropriate wetting 
agent for optimum dispersion of the drug at the lowest 
effective concentrations excess wetting agent can produce 
foaming and impart an unpleasant taste.  Eg.Polysorbate 80, 
Sodium lauryl sulfate.  
Other excipients
[16] 
The other excipients include buffers, preservatives, flavors and 
colors.  
Buffers are used to maintain the optimal pH for all excipients. 
Suspension pH is often adjusted to ensure that the drug 
remains insoluble.Eg.Sodium citrate  
Preservatives are required in most suspensions because the 
suspending agents and sweetener are good media for growth 
of microorganisms. Eg. Sorbic acid. Sucrose in sufficient 
concentrations (60%w/w) can aid in the prevention of 
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microbial growth. Other common preservatives used are 
Sodium benzoate and Sodium propionate.   
Flavors enhance patient acceptability of product. Both natural 
and artificial flavors are used. Additional flavors used include 
raspberry, pineapple etc. In some cases refrigeration after 
reconstitution is required for the stability of the flavoring 
agent rather than for the stability of the drug.   
Colorants are intended to provide a more aesthetic appearance 
to the final suspension.  
Anticaking agents such as amorphous silica gel have many 
functions in suspensions for reconstitution. A common 
problem in dry mixtures is poor powder flow and caking. This 
is often caused by powder agglomeration due to moisture 
uptake. 
Method of preparation of dry mixture
[17]
 
Mostly antibiotics are available in dry syrup form. Dry syrup 
is manufactured in three methods namely:  
1. Direct Mixing,  
2. Dry Granulation (Slugging) and  
3. Wet Granulation (wet massing) 
1. Flow Chart of Direct Mixing 
 
Process of direct mixing is summarized in fig no. 1.  
 
 
Fig no. 1: Direct mixing 
2. Flow chart of dry granulation 
Process of dry granulation is shown in fig no. 2. 
 
Fig no.2: Dry granulation process 
3. Flow chart of wet granulation 
Wetgranulation is one of the methods of preparation 
of dry syrup which is shown in fig no. 3. 
 
Fig no. 3: Wet granulation 
Preparation of dry mixture 
[13, 18] 
 Direct mixing 
 Granulated products  
 Combination products 
Direct mixing 
Process of direct mixing with their advantages and 
disadvantages shown in table no. 2 
Table no. 2: Direct mixing 
Powder blend Advantages Disadvantages 
Also called 
powder mixtures, 
are prepared by 
mixing the 
Excipients of dry 
mixture in 
powder form. 
Excipients 
Present in small 
quantities may 
require a two 
stage mixing 
operation. 
Least capital 
equipment and 
energy 
Less chemical & 
physical 
stability problems 
because no 
heat or solvents 
are used 
Loss of active 
ingredient during 
mixing. 
Prone to 
homogeneity 
problem. 
 
The selection of the appropriate mixer involves several 
considerations, the most significant of which is that the mixer 
should rapidly and constantly produce a homogenous mixture.    
 
The equipment used is mixers. Few types of mixers are 
discussed below. 
1. Dry mixer 
2. Paddle mixer 
3. Vertical screw mixer 
4. Double cone mixer 
5. V blender 
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Dry mixer: For batch work the dry mixer is commonly used. 
This consists of a semi-cylindrical trough, usually covered and 
provided with two or more ribbon spirals. One spiral is 
righthanded and the other left-handed so that the material is 
worked back and forth in the trough. A broad ribbon lifts and 
conveys the materials while a narrow one will cut through the 
materials while conveying. Ribbon blenders are often used on 
the large scale and may be adapted for continuous mixing. Dry 
mixer is shown in fig no. 4. 
 
Fig no. 4: Dry mixer 
Paddle mixer: It has a stationary outer vessel and the powders 
are agitated by paddles rotating within. The equipment is 
suitable to heating, by jacketing the vessel, and also permits a 
kneading effect by the use of appropriately shaped paddles or 
beaters. This mixer is shown in fig no. 5. 
 
Fig no. 5: Paddle mixer 
Double cone mixer: A double cone mixer consists of a vessel 
with two cones base to base, with or without a cylindrical 
section in between. It is so mounted that it can be rotated 
about an axis at right angles to the line joining the points of 
the cones. Double cone mixer is an efficient mixer for mixing 
dry powder and granulates homogeneously. All the contact 
parts are made up of stainless steel. Two-third of the volume 
of the cone blender is filled to ensure proper mixing. This 
mixer shown in fig no. 6. 
 
Fig no. 6: Double cone mixer 
Features  
1. The conical shape at both ends enables uniform mixing 
and easy discharge.  
2. The cone is statically balanced to avoid any excessive 
load on the gear box and motor. 
3. While the powder can be loaded into the cone through a 
wider opening, it candischarged through a side valve.   
4. Depending upon the product, paddle type baffles can be 
provided on the shaft for better mixing. 
 
4. V- blenders: V blenders are used for dry mixing. They are 
totally enclosed to prevent any foreign particles to enter into 
the chamber. V blender shown in fig no. 7. 
 
Fig no. 7: V blender 
Features  
 • Minimal attrition when blending fragile granules.  
 • Large-capacity equipment available.  
• It is easier to clean and unload the blender  
 • Minimal maintenance is required   
• Available in various capacities from 25 litres to 1000 litres. 
Granulated products 
[18]
 
All the excipients in granulated products are processed by 
granulation. Wet granulation is the usual process and the 
granulating fluid is water or an aqueous binder solution. There 
are two methods of incorporating the drug. The drug can be 
dry blended with the other excipients or it can be dissolved or 
suspended in the granulating fluid.  
Advantages  
 Improved appearance  
 Improved flow characteristics  
 Less segregation problems  
 Less generation of dust during filling operations 
Disadvantages  
 Requires more capital investment and energy.  
 It is difficult to remove the last traces of granulating 
fluid from the interior of granules. Thus the residual 
fluid may reduce the stability of the product.  
 The excipients and drug must be stable to the 
granulation process.  
 Uniform granulation is necessary because an excess 
of very small particles, or fines, will result in rapid 
segregation 
The equipment used in this process are 
1. Planetary mixers 
2. Rotating sieve 
3. Fluid bed dryer 
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Planetary mixers: Planetary mixer shown in fig no. 8. The 
planetary mixer is used for mixing of dry and wet powders, 
light pastes, gels, and dough. The planetary mixer is so named 
because the mixing blade (commonly known as the beater) 
rotates in a planetary motion inside the mixer bowl. The bowl 
of the single planetary mixer consists of an upper cylindrical 
section and a lower hemispherical section. The mixer bowl is 
secured to a semi-circular frame (also termed as “fork”) at the 
time of mixing. The beater profiles are shaped to match the 
lower curved surface of the bowl. The beater has two types of 
movements: it revolves on its own vertical axis at high speed. 
At the same time, this vertical axis rotates around the centre of 
the bowl at a relatively lower speed. The direction of rotation 
of the beater on its own axis and that around the axis of the 
bowl is in opposite directions [13, 18]. 
 
Fig no. 8: Planetary mixer 
Rotating sieve: The rotating sieve mill guarantees optimum 
sizing results plus excellent flow rates. The 360-degree rotor 
movement ensures constant, uniform speed and force effect 
for gentle sizing of the product. The advantage of this process 
resides in an exceptionally low fine particle fraction in the end 
product, as well, the low mechanical stress allows for the 
capability of processing heat sensitive products. This sieve 
shown in fig no. 9. 
 
Fig no. 9: Rotating sieve 
Performance and Characteristics 
 • Easy installation, maintenance and long service life  
• All Stainless Steel in design   
• Large non-marking castors  
• Easy to clean Mirror polished side walls   
• No cross contamination  
• Low noise 
Fluid bed dryer: Moist material is fed onto a shaking 
perforated steel bed through which the drying air flows.  The 
air is of sufficient volume that it lifts, or fluidizes, the bed of 
material allowing intimate contact with each particle. The 
shaking action of the bed assists in the transportation of the 
material over the length of the dryer. Moisture is carried away 
by the air into a dust recovery system, whereby the hot air can 
be recycled in a closed loop back to the process.  The flow of 
air is controlled along the length of the dryer to maximize 
fluidization, enabling very wet and sticky materials to be 
handled.  As the material passes along the dryer it gradually 
loses moisture until the target dryness is achieved, at which 
point it passes into a cooling zone. Here the hot air is replaced 
by cool ambient air, which reduces the product temperature to 
the desired [19, 20]. 
Combination product [14, 16, 18]
 
Powdered and granulated excipients can be combined to 
overcome some disadvantages of granulated products. Less 
energy and equipment for granulation may be required if the 
majority of the diluents can be added after granulation. Also 
heat sensitive excipients such as flavors can be added after 
drying of the granulation to avoid exposure to elevated 
temperatures.   
The general method is first to granulate some of the 
excipients, then blending the remaining excipients with the 
dried granules before filling the container. The presence of the 
diluents helps to improve flow and reduces both segregation 
and dust formation.  
Disadvantages  
 Risk of non-uniformity 
 Particle sizes of various fractions should be carefully 
controlled 
Advantages and Disadvantages of types of Dry mixtures 
Dry mixtures have some advantages along with disadvantages 
which are discuss in table no. 3. 
Table no.3: Advantages and disadvantages of dry mixtures 
Type Advantage Disadvantage 
Powder blend 
Economy 
Low incidence of 
Instability 
Mixing & 
segregation 
Problems 
Losses of drugs 
Granulated 
products 
Appearance 
Flow 
characteristics 
Less segregation 
Less dust 
Cost 
Effects of heat & 
granulating fluid on 
drug & excipients 
Combination 
product 
 
Reduced cost 
Use of heat 
sensitive 
ingredients 
Ensuring non 
segragating 
mix of granular & 
nongranular 
ingredients 
 
Condition for manufacturing Dry Syrup:[17]
 
For manufacturing of dry syrup following conditions should 
be maintained. 
 Relative humidity: Not more than 60%. 
 Temperature: Below 25°C 
 All relevant materials are removed 
 Equipment is cleaned 
 Balanced is calibrate  
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 Bottle drying date 
 
Evaluation of oral reconstitutable suspension
[14] 
After preparation of reconstitutable suspension it will evaluate 
for below parameters. 
(1) Flow properties: Flow properties such as angle of repose, 
bulk density, tap density and porosity of powder 
mixture,granulations and combination product should be 
carried out.   
(2) Rheological behavior: The rheological behavior of the 
reconstituted suspensions is determined using Brookefield 
viscometer (Model – RVT).   
(3) Sedimentation behavior:- 
a.) Redispersibility: The redispersibility is determined by 
studying the number of strokes to redisperse the formed 
sediment at the end of 7 days of storage of the 
formulations (not more than 100 strokes = 
Redispersibility).   
b.) Sedimentation Volume Ratio (SVR): Sedimentation 
volume of a suspension is expressed by the ratio of the 
equilibrium volume of the sediment, Vu, to the total 
volume, Vo of the suspensioni.e. F=Vu/VoThe value of F 
normally lies between 0 to 1 for any pharmaceutical 
suspension. The value of F provides a qualitative 
knowledge about the physical stability of the suspension.   
(4) Drug content: The required weight of drug mixture is 
taken and extracted with 100ml solvent and solution is 
filtered through nylon filter membrane. 0.1ml of the 
solution is further diluted to 10ml with solvent and 
absorbance of the solution is read on UV Spectroscopy. 
The drug concentration is extrapolated from the 
calibration curve in solvent.  
(5) In vitro drug release: The in vitro dissolution studies were 
carried out using USP apparatus Type II at 100 rpm. The 
dissolution medium consisted of 900 ml distilled water 
maintained at 37°C ± 0.50 C. The drug release at different 
time intervals was measured for two hours using UV 
spectrophotometer.   
(6) Particle size: The oral reconstitutable suspension is 
evaluated, the average particle size of the formulation is 
examined using standard microscopy method average and 
standard deviations of 100 particles are estimated.   
(7) Viscosity: The rheological behavior of the suspension is 
determined by using Brookfield viscometer (Model -
LVDI).  
(8) Zeta potential measurement: Suspension is diluted with 
distilled water and the measurements are taken in 
triplicate.   
(9) Stability study: The reconstitutable suspension is stored in 
air tight amber coloured glass bottles for 36 days at 45°C 
and then reconstituted with distilled water to make up the 
volume to 60 ml with gentle shaking. The reconstituted 
suspension is stored at 4°C, 25°C and 45°C for 15 days. 
(10) pH values: The pH of suspensions was measured with the 
aid of a pH meter. 
 
 
Packaging and storage 
[16]
 
Dry powder for reconstitution packaged in wide mouth 
container or in sachet in case of unit dosing. 
1. The dry powders for reconstitution should be packaged in 
wide mouth container having sufficient air space above 
the liquid.  
2. The dry powders should be stored in tight container 
protected from freezing, excessive  heatand light.  
3. The label should contain the direction stating: "Shake 
Before Use" to ensure uniform  distribution of solid 
particles and thereby to obtain uniform and proper 
dosage.  
4. The dry powders should be stored at room temperature. 
5. After reconstitution the suspension should be stored in the 
refrigerator (freezing should be avoided to prevent 
aggregation) 
6. For single dosage packing, sachets are used made up of 4 
layers of aluminum foil.    
 
ICH guidelines (q6a) for reconsitutable oral suspensions 
[14, 21, 22]
 
International conference on harmonization (ICH) provides 
some guidelines for reconstitutable oral suspension. 
a) Uniformity of dosage units: This term includes both the 
mass of the dosage form and the content of the active 
substance in the dosage form; a pharmacopoeial procedure 
should be used. In general, the specification should include 
one or the other but not both. When weight variation is applied 
for new drug products exceeding the threshold value to allow 
testing uniformity by weight variation, applicants should 
verify during drug development that the homogeneity of the 
product is adequate.    
If appropriate, tests may be performed in-process; however, 
the acceptance criteria should be included in the specification. 
This concept may be applied to both single-dose and multiple 
dose packages. The dosage unit is considered to be the typical 
dose taken by the patient.  
If dispensing equipment (such as medicine droppers or 
dropper tips for bottles) is an integral part of the packaging, 
this equipment should be used to measure the dose. Otherwise, 
a standard volume measure should be used. For powders for 
reconstitution, uniformity of mass testing is generally 
considered acceptable.    
b) pH: Acceptance criteria for pH should be provided where 
applicable and the proposed range justified.    
c) Microbial limits: Microbial limit testing is seen as an 
attribute of Good Manufacturing Practice, as well as of quality 
assurance. In general, it is advisable to test the drug product 
unless its components are tested before manufacture and the 
manufacturing process is known, through validation studies, 
not to carry a significant risk of microbial contamination or 
proliferation. It should be noted that, whereas this Guideline 
does notdirectly address excipients, the principles discussed 
here may be applicable to excipients as well as to new drug 
products. With acceptable scientific justification, it may be 
possible to propose no microbial limit testing for powders 
intended for reconstitution as oral liquids.    
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Acceptance criteria should be set for the total count of aerobic 
microorganisms, total count of yeasts and molds, and the 
absence of specific objectionable bacteria (e.g., 
Staphylococcus aureus, Escherichia coli, Salmonella, 
Pseudomonas aeruginosa). These should be determined by 
suitable procedures, using pharmacopoeial procedures, and at 
a sampling frequency or time point in manufacture which is 
justified by data and experience. Decision tree #8 provides 
additional guidance on the use of microbial limits testing.    
d) Antimicrobial preservative content: For oral liquids needing 
an antimicrobial preservative, acceptance criteria for 
preservative content should be established. Acceptance criteria 
for preservative content should be based upon the levels of 
antimicrobial preservative necessary to maintain 
microbiological quality of the product at all stages throughout 
its proposed usage and shelf-life. Testing for antimicrobial 
preservative content should normally be performed at release.  
Under certain circumstances, in-process testing may suffice in 
lieu of release testing.    
When antimicrobial preservative content testing is performed 
as an in-process test, the acceptance criteria should remain 
part of the specification. Antimicrobial preservative 
effectiveness should be demonstrated during development, 
during scaleup, and throughout the shelf-life (e.g., in stability 
testing: see the ICH Guideline, “Stability Testing of New 
Drug Substances and Products”), although chemical testing for 
preservative content is the attribute normally included in the 
specification.   
e) Antioxidant preservative content: Release testing for 
antioxidant content should normally be performed. Under 
certain circumstances, where justified by developmental and 
stability data, shelf-life testing may be unnecessary, and in-
process testing may suffice in lieu of release testing where 
permitted. When antioxidant content testing is performed as an 
inprocess test, the acceptance criteria should remain part of the 
specification.  
f) Extractable: Generally, where development and stability 
data show evidence that extractable from the container/closure 
systems are consistently below levels that aredemonstrated to 
be acceptable and safe, elimination of this test can normally be 
accepted. This should be reinvestigated if the 
container/closure system or formulation changes.  
g) Alcohol content: Where it is declared quantitatively on the 
label in accordance with pertinent regulations, the alcohol 
content should be specified. It may be assayed or calculated.    
h) Dissolution: In addition to the attributes recommended 
immediately above, it may be appropriate (e.g., insoluble drug 
substance) to include dissolution testing and acceptance 
criteria for oral suspensions and dry powder products for 
resuspension. Dissolution testing should be performed at 
release. Dissolution procedures using either pharmacopoeial or 
non-pharmacopoeial apparatus or conditions should be 
validated. Singlepoint measurements are normally considered 
suitable for immediate-release dosage forms. Multiple-point 
sampling, at appropriate intervals, should be performed for 
modifiedrelease dosage forms. Developmental data should be 
considered when determining the need for either a dissolution 
procedure or a particle size distribution procedure.   
i) Particle size distribution: Quantitative acceptance criteria 
and a procedure for determination of particle size distribution 
may be appropriate for oral suspensions. Developmental data 
should be considered when determining the need for either a 
dissolutionprocedure or a particle size distribution procedure 
for these formulations. Particle size distribution testing should 
be performed at release. Particle size distribution testing may 
also be proposed in place of dissolution testing; justification 
should be provided. The acceptance criteria should include 
acceptable particle size distribution in terms of the percent of 
total particles in given size ranges.  
j) Redispersibility: For oral suspensions which settle on 
storage (produce sediment), acceptance criteria for 
redispersibility may be appropriate. Shaking may be an 
appropriate procedure. The procedure (mechanical or manual) 
should be indicated. Time required to achieve resuspension by 
the indicated procedure should be clearly defined. 
k) Rheological properties: For relatively viscous solutions or 
suspensions, it may be appropriate to include rheological 
properties (viscosity/specific gravity) in the specification. The 
test and acceptance criteria should be stated. Data generated 
during product development may be sufficient to justify skip 
lot testing, or elimination of this attribute from the 
specification may be proposed.    
l) Reconstitution time: Acceptance criteria for reconstitution 
time should be provided for dry powder products which 
require reconstitution. The choice of diluent should be 
justified. Data generated during product development may be 
sufficient to justify skip lot testing or elimination of this 
attribute from the specification may be proposed.   
Typical Reconstitutable Oral Suspensions 
Some reconstitutable oral suspension mentioned in table no. 4. 
Table no. 4: Reconstitutable oral suspensions 
Drug Manufacturers 
Amoxicillin trihydrate SmithklineBeecham 
Ampicillin Biocraft 
Cefalexin Dista 
Dicloxacillin sodium Apothecan 
Erythromycin 
ethylsuccinate 
Abbott 
Ampicillin &probencid Biocraft 
 
Future Perspective: Sustained release powder for oral 
suspension formulate by using sustained release polymer. 
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